- Acquisition adds potential best-in-class disease-modifying
therapy for Alzheimer's disease, ALIA-1758, and novel blood-brain
barrier (BBB)-crossing technology to strengthen neuroscience
pipeline and R&D capabilities
NORTH
CHICAGO, Ill., Dec. 11,
2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced
today that it has completed its acquisition of Aliada Therapeutics.
With the completion of the acquisition, Aliada is now a part of
AbbVie.
Aliada's lead investigational asset is ALIA-1758, an
anti-pyroglutamate amyloid beta (3pE-Aβ) antibody, which is in
development for the treatment of patients with Alzheimer's disease
and is currently in a Phase 1 clinical trial. ALIA-1758 utilizes a
novel blood-brain barrier (BBB)-crossing technology that enhances
delivery of targeted drugs into the central nervous system
(CNS).
"Alzheimer's disease poses a significant public health
challenge, impacting millions worldwide and is becoming more
prevalent as populations age," said Dawn
Carlson, M.D., M.P.H., vice president, neuroscience
development at AbbVie. "With the acquisition now complete, we look
forward to advancing potentially disease-modifying therapies such
as ALIA-1758 for Alzheimer's disease and bolstering our
neuroscience discovery and development efforts by leveraging
Aliada's novel CNS drug delivery platform."
For additional background on the acquisition, please read the
announcement press release here.
About AbbVie
AbbVie's mission is to discover and deliver innovative medicines
and solutions that solve serious health issues today and address
the medical challenges of tomorrow. We strive to have a remarkable
impact on people's lives across several key therapeutic areas –
immunology, oncology, neuroscience, and eye care – and products and
services in our Allergan Aesthetics portfolio. For more information
about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on
LinkedIn, Facebook, Instagram, X (formerly Twitter), and
YouTube.
Forward-Looking Statements
Some statements in this news release are, or may be
considered, forward-looking statements for purposes of the Private
Securities Litigation Reform Act of 1995. The words "believe,"
"expect," "anticipate," "project" and similar expressions and uses
of future or conditional verbs, generally identify forward-looking
statements. AbbVie cautions that these forward-looking statements
are subject to risks and uncertainties that may cause actual
results to differ materially from those expressed or implied in the
forward-looking statements. Such risks and uncertainties include,
but are not limited to, challenges to intellectual property,
competition from other products, difficulties inherent in the
research and development process, adverse litigation or government
action, and changes to laws and regulations applicable to our
industry. Additional information about the economic, competitive,
governmental, technological and other factors that may affect
AbbVie's operations is set forth in Item 1A, "Risk Factors," of
AbbVie's 2023 Annual Report on Form 10-K, which has been filed with
the Securities and Exchange Commission, as updated by its
subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no
obligation, and specifically declines, to release publicly any
revisions to forward-looking statements as a result of subsequent
events or developments, except as required by law.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/abbvie-completes-acquisition-of-aliada-therapeutics-302329026.html
SOURCE AbbVie